Interferon gamma-1b is a therapeutic protein that is a recombinant form of human interferon gamma [1]. It is primarily used to treat chronic granulomatous disease (CGD), a rare genetic disorder that affects the immune system's ability to fight off infections [2]. In CGD patients, it helps reduce the frequency and severity of serious infections [3].
How does Interferon gamma-1b work?
Interferon gamma-1b functions by stimulating certain immune cells, such as macrophages, to increase their ability to destroy bacteria and other pathogens [1][4]. It also plays a role in regulating the immune response [4].
What other conditions might Interferon gamma-1b be used for?
While its primary approved indication is for CGD, interferon gamma-1b has been investigated for other conditions, including certain types of cancer and wound healing, though its use in these areas may be off-label or part of ongoing research [5].
When does patent exclusivity for Interferon gamma-1b expire?
The patent exclusivity for specific interferon gamma-1b products, like Actimmune, has expired or is nearing expiration. DrugPatentWatch.com tracks these patent and exclusivity timelines, which are crucial for understanding when generic or biosimilar versions might become available [6]. For instance, the patent for Actimmune expired in the United States in 2009 [6].
Can biosimilar versions of Interferon gamma-1b be developed?
As patent exclusivity periods end, the development of biosimilar versions of biologic drugs like interferon gamma-1b becomes possible [7]. Biosimilars are highly similar to the reference product and have no clinically meaningful differences in terms of safety, purity, and potency [7]. The pathway for biosimilar approval involves demonstrating similarity to the reference product through extensive analytical, non-clinical, and clinical studies [7].
What are the side effects of Interferon gamma-1b?
Common side effects associated with interferon gamma-1b therapy include flu-like symptoms such as fever, headache, fatigue, muscle aches, and chills [2][3]. Other potential side effects can include nausea, diarrhea, and injection site reactions [3]. Patients should discuss any potential side effects with their healthcare provider [2].
How is Interferon gamma-1b administered?
Interferon gamma-1b is typically administered through subcutaneous injection [2][3]. The dosage and frequency of administration are determined by a healthcare professional based on the patient's condition and response to treatment [3].
Sources:
[1] https://www.drugbank.ca/drugs/DB00023
[2] https://www.cancer.gov/publications/patient-education/interferongammab
[3] https://medlineplus.gov/druginfo/meds/a607009.html
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556565/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306777/
[6] https://drugpatentwatch.com/
[7] https://www.fda.gov/drugs/biosimilars/understanding-biosimilars